These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15580607)

  • 1. Trial of subtherapeutic pergolide in de novo Parkinson's disease.
    Grosset K; Grosset D; Lees A;
    Mov Disord; 2005 Mar; 20(3):363-6. PubMed ID: 15580607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
    Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
    Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Nov; 18(11):1324-31. PubMed ID: 14639675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients.
    Kulisevsky J; López-Villegas D; García-Sánchez C; Barbanoj M; Gironell A; Pascual-Sedano B
    Clin Neuropharmacol; 1998; 21(6):358-62. PubMed ID: 9844794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
    Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
    Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both.
    Ozer F; Tiras R; Cetin S; Ozturk O; Aydemir T; Ozben S; Meral H; Kizkin S; Bader H; Ozben B
    J Clin Neurosci; 2009 Jan; 16(1):83-7. PubMed ID: 19014887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.
    Oertel WH; Wolters E; Sampaio C; Gimenez-Roldan S; Bergamasco B; Dujardin M; Grosset DG; Arnold G; Leenders KL; Hundemer HP; Lledó A; Wood A; Frewer P; Schwarz J
    Mov Disord; 2006 Mar; 21(3):343-53. PubMed ID: 16211594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease.
    Singer C; Lamb J; Ellis A; Layton G;
    Mov Disord; 2007 Mar; 22(4):476-82. PubMed ID: 17318839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
    Storch A; Jost WH; Vieregge P; Spiegel J; Greulich W; Durner J; Müller T; Kupsch A; Henningsen H; Oertel WH; Fuchs G; Kuhn W; Niklowitz P; Koch R; Herting B; Reichmann H;
    Arch Neurol; 2007 Jul; 64(7):938-44. PubMed ID: 17502459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease.
    Barone P; Lamb J; Ellis A; Clarke Z
    Mov Disord; 2007 Mar; 22(4):483-9. PubMed ID: 17115380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
    Murata M; Hasegawa K; Kanazawa I;
    Neurology; 2007 Jan; 68(1):45-50. PubMed ID: 17200492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.
    Hersh BP; Earl NL; Hauser RA; Stacy M
    Mov Disord; 2010 May; 25(7):927-31. PubMed ID: 20461810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA; Holford NH
    Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.